You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFinasteride
Accession NumberDB01216  (APRD00632, DB07774)
TypeSmall Molecule
GroupsApproved
Description

An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem]

Structure
Thumb
Synonyms
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
Finasterida
Finasteridum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-finasteride Tablets USPtablet5 mgoralAccel Pharma IncNot applicableNot applicableCanada
Ach-finasteridetablet5 mgoralAccord Healthcare Inc2010-10-04Not applicableCanada
Act Finasteridetablet5 mgoralActavis Pharma Company2010-11-17Not applicableCanada
Ag-finasteridetablet5 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-finasteridetablet5 mgoralAuro Pharma Inc2013-05-30Not applicableCanada
Auro-finasteride 1mgtablet1 mgoralAuro Pharma Inc2014-11-12Not applicableCanada
Dom-finasteridetablet5 mgoralDominion Pharmacal2013-06-13Not applicableCanada
Finasteridetablet5 mgoralMeliapharm Inc2011-07-272014-06-25Canada
Finasteridetablet5 mgoralSanis Health Inc2015-10-14Not applicableCanada
Finasteridetablet1 mgoralSivem Pharmaceuticals Ulc2015-11-25Not applicableCanada
Finasteridetablet5 mgoralPro Doc Limitee2010-04-29Not applicableCanada
Finasteridetablet5 mgoralSivem Pharmaceuticals Ulc2015-11-25Not applicableCanada
Finasteridetablet1 mgoralSanis Health Inc2015-10-14Not applicableCanada
Jamp-finasteridetablet5 mgoralJamp Pharma Corporation2010-10-21Not applicableCanada
Mint-finasteridetablet5 mgoralMint Pharmaceuticals Inc2012-07-25Not applicableCanada
Mylan-finasteridetablet5 mgoralMylan Pharmaceuticals Ulc2010-09-10Not applicableCanada
Mylan-finasteride Hgtablet1 mgoralMylan Pharmaceuticals Ulc2015-01-30Not applicableCanada
Ntp-finasteridetablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PMS-finasteridetablet1 mgoralPharmascience Inc2010-05-13Not applicableCanada
PMS-finasteridetablet5 mgoralPharmascience Inc2010-03-17Not applicableCanada
Propeciatablet, film coated1 mg/1oralMerck Sharp & Dohme Corp.1997-12-19Not applicableUs
Propeciatablet1 mgoralMerck Canada Inc1998-07-09Not applicableCanada
Propeciatablet, film coated1 mg/1oralbryant ranch prepack1997-12-19Not applicableUs
Propeciatablet, film coated1 mg/1oralPhysicians Total Care, Inc.1997-12-19Not applicableUs
Proscartablet5 mgoralMerck Canada Inc1992-12-31Not applicableCanada
Proscartablet, film coated5 mg/1oralMerck Sharp & Dohme Corp.1992-06-19Not applicableUs
Ran-finasteridetablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-09-28Not applicableCanada
Ratio-finasteridetablet5 mgoralTeva Canada Limited2010-03-17Not applicableCanada
Sandoz Finasteridetablet5 mgoralSandoz Canada Incorporated2010-02-01Not applicableCanada
Sandoz Finasteride Atablet1 mgoralSandoz Canada Incorporated2010-05-12Not applicableCanada
Teva-finasteridetablet5 mgoralTeva Canada Limited2010-04-07Not applicableCanada
Van-finasteridetablet5 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-finasteridetablet5 mgoralApotex Inc2011-11-17Not applicableCanada
Finasteridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2007-05-012015-12-29Us
Finasteridetablet, film coated1 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Finasteridetablet, film coated5 mg/1oralProficient Rx LP2010-05-11Not applicableUs
Finasteridetablet, film coated5 mg/1oralIngenus Pharmaceuticals, LLC2011-08-01Not applicableUs
Finasteridetablet5 mg/1oralAidarex Pharmaceuticals LLC2012-10-25Not applicableUs
Finasteridetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2006-12-15Not applicableUs
Finasteridetablet, film coated1 mg/1oralREMEDYREPACK INC.2015-06-16Not applicableUs
Finasteridetablet, film coated1 mg/1oralCitron Pharma LLC2013-11-05Not applicableUs
Finasteridetablet, film coated5 mg/1oralMylan Institutional Inc.2015-07-13Not applicableUs
Finasteridetablet, film coated5 mg/1oralExelan Pharmaceuticals Inc.2015-05-22Not applicableUs
Finasteridetablet, film coated5 mg/1oralAmerican Health Packaging2012-02-17Not applicableUs
Finasteridetablet, film coated5 mg/1oralAv Pak2007-03-28Not applicableUs
Finasteridetablet, film coated5 mg/1oralCamber Pharmaceuticals, Inc.2015-06-13Not applicableUs
Finasteridetablet, film coated5 mg/1oralREMEDYREPACK INC.2015-06-10Not applicableUs
Finasteridetablet, film coated5 mg/1oralCardinal Health2011-07-08Not applicableUs
Finasteridetablet, film coated5 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Finasteridetablet5 mg/1oralHetero Drugs Limited2010-06-07Not applicableUs
Finasteridetablet, film coated5 mg/1oralSun Pharma Global FZE2011-08-18Not applicableUs
Finasteridetablet, film coated5 mg/1oralAccord Healthcare, Inc.2010-05-11Not applicableUs
Finasteridetablet, film coated5 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Finasteridetablet5 mg/1oralDr. Reddy's Laboratories Limited2007-02-28Not applicableUs
Finasteridetablet1 mg/1oralCipla USA Inc.2014-11-20Not applicableUs
Finasteridetablet, film coated1 mg/1oralAurobindo Pharma Limited2014-09-20Not applicableUs
Finasteridetablet, film coated1 mg/1oralHetero Labs Limited2013-07-01Not applicableUs
Finasteridetablet, film coated1 mg/1oralSun Pharma Global FZE2013-07-01Not applicableUs
Finasteridetablet, film coated1 mg/1oralAccord Healthcare, Inc.2013-11-05Not applicableUs
Finasteridetablet, film coated5 mg/1oralREMEDYREPACK INC.2015-03-20Not applicableUs
Finasteridetablet, film coated1 mg/1oralDr. Reddy's Laboratories Limited2013-01-02Not applicableUs
Finasteridetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-06Not applicableUs
Finasteridetablet, film coated5 mg/1oralAurobindo Pharma Limited2007-10-30Not applicableUs
Finasteridetablet, film coated5 mg/1oralUnit Dose Services2011-08-18Not applicableUs
Finasteridetablet, film coated1 mg/1oralActavis Inc.2013-11-05Not applicableUs
Finasteridetablet, film coated5 mg/1oralNorth Star Rx Llc2011-05-16Not applicableUs
Finasteridetablet, film coated5 mg/1oralGreenstone LLC2007-10-302016-02-29Us
Finasteridetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2006-06-30Not applicableUs
Finasteridetablet, film coated1 mg/1oralPreferred Pharmaceuticals, Inc.2013-02-06Not applicableUs
Finasteridetablet, film coated5 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-22Not applicableUs
Finasteridetablet, film coated1 mg/1oralDr Reddys Laboratories Inc2014-06-10Not applicableUs
Finasteridetablet, film coated5 mg/1oralActavis Pharma, Inc.2007-03-28Not applicableUs
Finasteridetablet, film coated5 mg/1oralQualitest Pharmaceuticals2006-12-22Not applicableUs
Finasteridetablet, film coated5 mg/1oralNew Horizon Rx Group, LLC2013-08-13Not applicableUs
Finasteridetablet5 mg/1oralREMEDYREPACK INC.2013-05-292016-04-05Us
Finasteridetablet5 mg/1oralDr Reddys Laboratories Inc2012-10-25Not applicableUs
Finasteridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2015-10-20Not applicableUs
Finasteridetablet, film coated5 mg/1oralClinical Solutions Wholesale2006-12-15Not applicableUs
Finasteridetablet5 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Finasteridetablet, film coated1 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-20Not applicableUs
Finasteridetablet, film coated1 mg/1oralbryant ranch prepack2013-11-05Not applicableUs
Finasteridetablet, film coated1 mg/1oralCamber Pharmaceuticals, Inc.2013-07-01Not applicableUs
Finasteridetablet, film coated5 mg/1oralMylan Institutional Inc.2007-10-22Not applicableUs
Finasteridetablet, film coated5 mg/1oralLegacy Pharmaceutical Packaging2010-08-01Not applicableUs
Finasteridetablet, film coated5 mg/1oralbryant ranch prepack2007-10-30Not applicableUs
Finasteridetablet, film coated5 mg/1oralHetero Labs Limited2016-03-04Not applicableUs
Finasteridetablet, film coated5 mg/1oralAv Kare, Inc.2013-02-26Not applicableUs
Finasteridetablet5 mg/1oralKAISER FOUNDATION HOSPITALS2015-05-26Not applicableUs
Finasteridetablet, film coated5 mg/1oralCitron Pharma LLC2007-10-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FinastidNot Available
FinpeciaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII57GNO57U7G
CAS number98319-26-7
WeightAverage: 372.5441
Monoisotopic: 372.277678406
Chemical FormulaC23H36N2O2
InChI KeyInChIKey=DBEPLOCGEIEOCV-WSBQPABSSA-N
InChI
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
IUPAC Name
(1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-14-carboxamide
SMILES
[H][C@@]12CC[[email protected]](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassOxosteroids
Direct ParentOxosteroids
Alternative Parents
Substituents
  • 3-oxo-4-azasteroid
  • 3-oxo-5-alpha-steroid
  • Oxosteroid
  • 3-oxosteroid
  • Azasteroid
  • 4-azasteroid
  • Tetrahydropyridine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
PharmacodynamicsFinasteride is a synthetic 4-azasteroid compound. This drug is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT. Although finasteride is 100-fold more selective for type II 5a-reductase than for the type I isoenzyme, chronic treatment with this drug may have some effect on type I 5a-reductase.
Mechanism of actionThe mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-reductase through the formation of a stable complex with the enzyme. Inhibition of Type II 5a-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations, minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concetrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately 20-30% after 6-24 months of continued therapy). In men with androgenic alopecia, the mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found in hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 44 to 96 L
Protein bindingApproximately 90%
Metabolism

Drug is extensively metabolized, primarily in the liver via CYP3A4. Two metabolites have been identified with ≤20% of the activity of finasteride.

SubstrateEnzymesProduct
Finasteride
omega-hydroxyfinasterideDetails
Route of eliminationFollowing an oral dose of 14C-finasteride in man (n = 6), a mean of 39% (range, 32 to 46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51 to 64%) was excreted in the feces. Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites.
Half life4.5 hours (range 3.3-13.4 hours)
Clearance
  • 165 mL/min [healthy young subjects]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.9777
Caco-2 permeable-0.5496
P-glycoprotein substrateSubstrate0.7639
P-glycoprotein inhibitor IInhibitor0.7258
P-glycoprotein inhibitor IINon-inhibitor0.5558
Renal organic cation transporterNon-inhibitor0.7854
CYP450 2C9 substrateNon-substrate0.8062
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.9176
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7841
Ames testNon AMES toxic0.8581
CarcinogenicityNon-carcinogens0.9436
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9188 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9901
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral5 mg/1
Tabletoral1 mg
Tablet, film coatedoral1 mg/1
Tabletoral5 mg
Tablet, film coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Proscar 5 mg tablet3.64USD tablet
Finasteride 5 mg tablet3.19USD tablet
Propecia 1 mg tablet2.74USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1331601 No1994-08-232011-08-23Canada
CA2173457 No1999-03-232014-10-11Canada
US5942519 No1998-10-232018-10-23Us
US6046183 No1994-03-202011-03-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point252-254 °CPhysProp
water solubility11.7 mg/LNot Available
logP3.03HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00198 mg/mLALOGPS
logP3.53ALOGPS
logP3.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)14.53ChemAxon
pKa (Strongest Basic)2.22ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity108.2 m3·mol-1ChemAxon
Polarizability43.93 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Roman Davis, Alan Millar, “Method for preparing finasteride.” U.S. Patent US5670643, issued October, 1992.

US5670643
General References
  1. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13. [PubMed:20460827 ]
  2. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
External Links
ATC CodesD11AX10G04CA51G04CB01
AHFS Codes
  • 84:92.00
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (103 KB)
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sterol 5-alpha reductase activity
Specific Function:
Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A2
Uniprot ID:
P31213
Molecular Weight:
28393.015 Da
References
  1. Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM: Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003 Aug;74(2):393-406. Epub 2003 May 28. [PubMed:12773767 ]
  2. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707 ]
  3. Ha SJ, Kim JS, Myung JW, Lee HJ, Kim JW: Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. J Dermatol Sci. 2003 Apr;31(2):135-41. [PubMed:12670724 ]
  4. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13. [PubMed:20460827 ]
  5. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
  6. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428 ]
  7. Joseph MA, Jayaseelan E, Ganapathi B, Stephen J: Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat. 2005 Apr;16(2):75-8. [PubMed:16019620 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Electron carrier activity
Specific Function:
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A1
Uniprot ID:
P18405
Molecular Weight:
29458.18 Da
References
  1. Thigpen AE, Russell DW: Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem. 1992 Apr 25;267(12):8577-83. [PubMed:1314830 ]
  2. Levy MA, Brandt M, Sheedy KM, Holt DA, Heaslip JI, Trill JJ, Ryan PJ, Morris RA, Garrison LM, Bergsma DJ: Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):307-19. [PubMed:7734398 ]
  3. Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA Jr, et al.: 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry. 1994 Mar 1;33(8):2291-6. [PubMed:8117686 ]
  4. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13. [PubMed:20460827 ]
  5. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-cholesten-3-one can also act as substrates.
Gene Name:
AKR1D1
Uniprot ID:
P51857
Molecular Weight:
37376.615 Da
References
  1. Drury JE, Di Costanzo L, Penning TM, Christianson DW: Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J Biol Chem. 2009 Jul 24;284(30):19786-90. doi: 10.1074/jbc.C109.016931. Epub 2009 Jun 10. [PubMed:19515843 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995 Oct;23(10):1126-35. [PubMed:8654202 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 30, 2016 02:07